Which intravenous iron formulations are available and which is considered the most effective and safest option for treating iron‑deficiency anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Available IV Iron Formulations and Best Choice

For most patients requiring intravenous iron, ferric carboxymaltose (FCM) or ferric derisomaltose (FDI) are the preferred formulations, as they allow complete iron replacement (1000 mg) in a single 15-30 minute infusion with comparable safety profiles, though FCM should be avoided when hypophosphatemia risk is a concern 1.

Available IV Iron Formulations

The following formulations capable of total dose infusion (≥1000 mg in single visit) are available 1:

  • Low molecular weight iron dextran (LMWID) - 1000 mg in 250 mL over 60 minutes
  • Ferumoxytol (brand) - 1020 mg in 100 mL over 30 minutes
  • Ferric carboxymaltose (FCM) - 1000 mg over 15-30 minutes
  • Ferric derisomaltose (FDI) - 1000 mg in single infusion
  • Ferumoxytol generic - Same dosing as brand but with safety concerns

Note: Iron sucrose and ferric gluconate are older formulations limited to 200-250 mg per dose due to higher labile iron release, requiring 4-7 visits for complete repletion, making them suboptimal for ambulatory patients 1.

Comparative Safety and Efficacy

Efficacy

All modern high-dose formulations demonstrate equivalent hemoglobin improvement and iron repletion when comparing head-to-head studies 1, 2. FCM shows slightly faster iron store repletion over 4-8 weeks, but differences attenuate by 12-24 weeks 2.

Safety Profile

Infusion reactions: All modern formulations have comparable rates of moderate-to-severe reactions affecting <1-3% of patients 1, 3. The 2012 study showing higher adverse events with iron sucrose (OR=5.7) is less relevant given its dose limitations 4.

Critical safety distinction - Hypophosphatemia: FCM causes the "6H syndrome" (hyperphosphaturic hypophosphatemia with high FGF23) in 50-74% of patients, potentially causing bone pain, osteomalacia, and fractures 3. This is a unique and clinically significant complication requiring phosphorus monitoring per FDA label 1. Other formulations do not require routine phosphorus monitoring 1.

Clinical Decision Algorithm

First-Line Choice:

  • Ferric derisomaltose (FDI) or ferumoxytol (brand) for most patients
    • Equal efficacy to FCM without hypophosphatemia risk
    • Single-dose administration (1000-1020 mg)
    • 15-30 minute infusion time
    • Safer long-term mineral profile 2

Alternative Choices:

Use FCM when:

  • Rapid iron repletion is critical (4-8 week timeframe)
  • Phosphorus monitoring is feasible and reliable
  • Patient has no bone disease risk factors
  • Short-term treatment only 2

Use LMWID when:

  • Cost is primary consideration
  • Other formulations unavailable
  • Administer 1000 mg in 250 mL over 60 minutes (not the outdated 100 mg bolus method) 1
  • Despite black box warning in US (not in Europe), safety data supports single-dose administration 1

Use ferumoxytol when:

  • Notify radiology if MRI planned within 8 weeks (MRI contrast properties)
  • Administer 1020 mg over 30 minutes, NOT the original 17-second injection that caused high reaction rates 1

Avoid:

  • Ferumoxytol generic - Double the infusion reaction rate of brand, with one reported death in FDA filing of only 60 patients; lacks published safety data 1
  • Iron sucrose/ferric gluconate - Require multiple visits (4-7) for complete repletion, increasing extravasation risk and patient burden 1

Administration Pearls

For all formulations 1:

  • Start infusion slowly for 5 minutes to monitor for reactions
  • If no reaction, complete remaining infusion over labeled time
  • Rechallenge with same formulation is acceptable after minor infusion reaction
  • Have emergency equipment available but serious reactions are rare (<1%)

Common Pitfalls

  1. Confusing anaphylaxis with infusion reactions - True anaphylaxis is vanishingly rare; most reactions are infusion-related and manageable 1

  2. Using outdated administration methods - The 100 mg LMWID bolus or 17-second ferumoxytol injection are obsolete and increase reaction rates 1

  3. Ignoring hypophosphatemia with FCM - This affects majority of patients and can cause irreversible bone complications; requires clinical symptom monitoring and potential phosphorus supplementation 1, 3

  4. Accepting generic substitution without awareness - Pharmacists may substitute ferumoxytol generic; prescribers should specify brand when safety is prioritized 1

  5. Multiple low-dose visits - Using iron sucrose/ferric gluconate in ambulatory settings wastes resources and increases cumulative adverse event risk 1

References

3
Research

Intravenous iron supplementation therapy.

Molecular aspects of medicine, 2020

Related Questions

In a woman with iron‑deficiency anemia who cannot tolerate oral iron, should I administer intravenous iron or intramuscular iron injection?
What is the recommended management for a patient who has recently started oral iron therapy?
What is the best intravenous iron formulation?
When should intravenous iron be given and what dosing regimen is recommended for an adult weighing at least 50 kg with hemoglobin less than 10 g/dL?
When is intravenous iron therapy indicated?
When should intravenous iron be given and what dosing regimen is recommended for an adult weighing at least 50 kg with hemoglobin less than 10 g/dL?
How should I safely titrate insulin glargine (Lantus) in a patient who is also taking Jardiamet (glibenclamide/metformin) 12.5 mg/1000 mg twice daily with meals?
In a patient with impaired renal function (serum creatinine 2.85 mg/dL) and mild hypokalemia (serum potassium 3.4 mmol/L), should potassium be supplemented orally (PO) or intravenously (IV)?
What are the commercial brand names of the commonly used intravenous iron infusion products?
Are seizures a contraindication for Spravato (esketamine) nasal spray?
In a patient 5 weeks pregnant (positive home pregnancy test, last menstrual period 5 weeks ago) presenting with brown vaginal discharge, what is the likely cause and recommended management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.